Abstract: An antenna device includes a plurality of dipole antennas and a port. Each of the dipole antennas is connected to the port. The plurality of dipole antennas is arranged around the port. Each of the plurality of dipole antennas includes two ends. The ends of the dipole antennas are arranged in a plurality of pairs. Each pair includes one end of one of the dipole antennas and one end of another one of the dipole antennas. The two ends in each pair are arranged in proximity to each other. One or more switches are configured to switch between (1) an omnidirectional state, in which the ends of the dipole antennas are not connected to each other; and (2) a directional state, in which the two ends in each of one or more of the pairs are connected to each other.

Abstract: A color film substrate and a method of manufacturing the same, a display substrate and a method of manufacturing the same and a display device are provided. The color film substrate includes: a base substrate; a plurality of pixel units arranged on the base substrate, each unit includes a plurality of sub-pixels; the pixel unit includes: a barrier including a first barrier arranged around a peripheral side of the pixel unit and a second barrier arranged between adjacent sub-pixels, and the plurality of sub-pixels include a first sub-pixel for color conversion and a second sub-pixel for scattering; a color conversion material layer arranged in the first sub-pixel; a scattering material layer arranged in the second sub-pixel; at least one of the first barrier and the second barrier is in a same layer as the scattering material layer (50), and has the same material as that of the scattering material layer.

Abstract: A battery housing includes: a tray including a first channel; an explosion-proof valve disposed on the tray, the first channel being in communication with the explosion-proof valve; at least one module transverse beam disposed in the tray and including an accommodating portion, at least a part of a bottom of the accommodating portion being depressed downward to form a groove, and an opening disposed at at least one end of the groove along a length direction of the module transverse beam; and a liquid cooling plate connected to an outside of a bottom of the module transverse beam, at least one connection channel being formed between the liquid cooling plate and the module transverse beam, and the opening of the at least one module transverse beam being in communication with the first channel through the connection channel.

Abstract: A battery pack and an electric vehicle are provided. The battery pack includes a tray and a heating component. The heating component is arranged within the tray, and the heating component includes multiple heating sections. In the heating component of the battery pack, heating powers of the multiple heating sections are different, and the multiple heating sections are respectively configured to heat multiple regions within the tray to balance an ambient temperature within the tray.

Abstract: Disclosed are an instant dissolving device by mass transfer and stretching with a cleaning structure and a dissolving method thereof. The dissolving device consists of a liquid inlet, a stretching repetition unit and a mass transfer unit, the stretching unit is sequentially composed of an upper fixed fluted disc, a movable fluted disc and a lower fixed fluted disc all with a plurality of through holes, and the upper fixed fluted disc and the lower fixed fluted disc are fixed to the dissolving device housing; the polymer gel solution is formed into a “uniform” solution after passing through the mass transfer unit. The dissolving device in the present invention is easy to install, and achieves instant dissolution of the polymers and improves the dissolution efficiency through the joint action of forced stretching and mass transfer by high gravity.

Abstract: Disclosed are an instant dissolving device by mass transfer and stretching with a cleaning structure and a dissolving method thereof. The dissolving device consists of a liquid inlet, a stretching repetition unit and a mass transfer unit, the stretching unit is sequentially composed of an upper fixed fluted disc, a movable fluted disc and a lower fixed fluted disc all with a plurality of through holes, and the upper fixed fluted disc and the lower fixed fluted disc are fixed to the dissolving device housing; the polymer gel solution is formed into a “uniform” solution after passing through the mass transfer unit. The dissolving device in the present invention is easy to install, and achieves instant dissolution of the polymers and improves the dissolution efficiency through the joint action of forced stretching and mass transfer by high gravity.

Abstract: The invention relates to a guide RNA (gRNA) comprising a guide sequence capable of targeting a Cas9 protein to a target sequence in an ICP6 gene of type 1-herpes simplex virus (HSV-1) to provide a specific cleavage event, wherein the target sequence comprises a GATC insertion as compared to a wild-type HSV-1. The invention also relates to a HSV-1 gene-editing system and a gene-editing method for generating a desired recombinant HSV-1 by using said gRNA.

Abstract: The present disclosure provides systems and methods for imaging-guided monitoring and modeling of retinal vascular occlusive conditions. An example integrated optical coherence tomography (OCT) and scanning laser ophthalmoscope (SLO) apparatus includes an OCT subsystem to acquire baseline OCT and OCT angiography (OCTA) volumes of a subject without dye before occlusion and subsequent OCT and OCTA volumes of the subject with dye after occlusion. The example apparatus includes an SLO subsystem including a laser controlled to adjust a laser to form a vascular occlusion at a location on a target vessel of the subject. The example apparatus includes a processor to process the OCT and OCTA volumes and feedback from the OCT subsystem and the SLO subsystem to determine a change in three-dimensional vasculature from before the vascular occlusion to after the vascular occlusion.

Abstract: Systems and methods to measure blood flow using optical coherence tomography are disclosed. An example method includes: performing scanning of a target with beam(s) of incident low coherence radiation, wherein the low coherence radiation is selected from one or more regions of the electromagnetic spectrum based on the target selected; acquiring spectroscopic information from scanning signals generated by the interaction of the incident low coherence radiation and the target; generating image signal data for the target from the scanning signals; processing the image signal data by selecting electro-magnetic property(-ies) related to the modulation of the low coherence radiation by variation of relative permittivity and conductivity of the target; performing a multivariate comparison of the selected electro-magnetic properties related to the modulation of the low coherence radiation by variation of relative permittivity and conductivity of the target; and quantifying motion property(-ies) of the target.

Abstract: The present disclosure provides systems and methods for imaging-guided monitoring and modeling of retinal vascular occlusive conditions. An example integrated optical coherence tomography (OCT) and scanning laser ophthalmoscope (SLO) apparatus includes an OCT subsystem to acquire baseline OCT and OCT angiography (OCTA) volumes of a subject without dye before occlusion and subsequent OCT and OCTA volumes of the subject with dye after occlusion. The example apparatus includes an SLO subsystem including a laser controlled to adjust a laser to form a vascular occlusion at a location on a target vessel of the subject. The example apparatus includes a processor to process the OCT and OCTA volumes and feedback from the OCT subsystem and the SLO subsystem to determine a change in three-dimensional vasculature from before the vascular occlusion to after the vascular occlusion.

Abstract: The invention provides packaged pharmaceutical preparations of Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula where the variables are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound.

Abstract: This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations. This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

Abstract: The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formula 1